InnoCare Pharma Ltd
SSE:688428

Watchlist Manager
InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd
SSE:688428
Watchlist
Price: 13.3 CNY -7.06% Market Closed
Market Cap: 11.2B CNY
Have any thoughts about
InnoCare Pharma Ltd?
Write Note

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of InnoCare Pharma Ltd.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
Not Available
Base Case Scenario
How do you feel about InnoCare Pharma Ltd?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about InnoCare Pharma Ltd

Provide an overview of the primary business activities
of InnoCare Pharma Ltd.

What unique competitive advantages
does InnoCare Pharma Ltd hold over its rivals?

What risks and challenges
does InnoCare Pharma Ltd face in the near future?

Summarize the latest earnings call
of InnoCare Pharma Ltd.

Show all valuation multiples
for InnoCare Pharma Ltd.

Provide P/S
for InnoCare Pharma Ltd.

Provide P/E
for InnoCare Pharma Ltd.

Provide P/OCF
for InnoCare Pharma Ltd.

Provide P/FCFE
for InnoCare Pharma Ltd.

Provide P/B
for InnoCare Pharma Ltd.

Provide EV/S
for InnoCare Pharma Ltd.

Provide EV/GP
for InnoCare Pharma Ltd.

Provide EV/EBITDA
for InnoCare Pharma Ltd.

Provide EV/EBIT
for InnoCare Pharma Ltd.

Provide EV/OCF
for InnoCare Pharma Ltd.

Provide EV/FCFF
for InnoCare Pharma Ltd.

Provide EV/IC
for InnoCare Pharma Ltd.

Show me price targets
for InnoCare Pharma Ltd made by professional analysts.

What are the Revenue projections
for InnoCare Pharma Ltd?

How accurate were the past Revenue estimates
for InnoCare Pharma Ltd?

What are the Net Income projections
for InnoCare Pharma Ltd?

How accurate were the past Net Income estimates
for InnoCare Pharma Ltd?

What are the EPS projections
for InnoCare Pharma Ltd?

How accurate were the past EPS estimates
for InnoCare Pharma Ltd?

What are the EBIT projections
for InnoCare Pharma Ltd?

How accurate were the past EBIT estimates
for InnoCare Pharma Ltd?

Compare the revenue forecasts
for InnoCare Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of InnoCare Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of InnoCare Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of InnoCare Pharma Ltd compared to its peers.

Compare the P/E ratios
of InnoCare Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing InnoCare Pharma Ltd with its peers.

Analyze the financial leverage
of InnoCare Pharma Ltd compared to its main competitors.

Show all profitability ratios
for InnoCare Pharma Ltd.

Provide ROE
for InnoCare Pharma Ltd.

Provide ROA
for InnoCare Pharma Ltd.

Provide ROIC
for InnoCare Pharma Ltd.

Provide ROCE
for InnoCare Pharma Ltd.

Provide Gross Margin
for InnoCare Pharma Ltd.

Provide Operating Margin
for InnoCare Pharma Ltd.

Provide Net Margin
for InnoCare Pharma Ltd.

Provide FCF Margin
for InnoCare Pharma Ltd.

Show all solvency ratios
for InnoCare Pharma Ltd.

Provide D/E Ratio
for InnoCare Pharma Ltd.

Provide D/A Ratio
for InnoCare Pharma Ltd.

Provide Interest Coverage Ratio
for InnoCare Pharma Ltd.

Provide Altman Z-Score Ratio
for InnoCare Pharma Ltd.

Provide Quick Ratio
for InnoCare Pharma Ltd.

Provide Current Ratio
for InnoCare Pharma Ltd.

Provide Cash Ratio
for InnoCare Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for InnoCare Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for InnoCare Pharma Ltd?

What is the current Free Cash Flow
of InnoCare Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for InnoCare Pharma Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
InnoCare Pharma Ltd

Balance Sheet Decomposition
InnoCare Pharma Ltd

Current Assets 9.3B
Cash & Short-Term Investments 9.1B
Receivables 144.6m
Other Current Assets 101.4m
Non-Current Assets 1B
Long-Term Investments 11.7m
PP&E 696.5m
Intangibles 276.3m
Other Non-Current Assets 44.6m
Current Liabilities 2.1B
Accounts Payable 118.6m
Accrued Liabilities 57m
Other Current Liabilities 1.9B
Non-Current Liabilities 664m
Long-Term Debt 35.4m
Other Non-Current Liabilities 628.6m
Efficiency

Earnings Waterfall
InnoCare Pharma Ltd

Revenue
625.4m CNY
Cost of Revenue
-143.4m CNY
Gross Profit
482m CNY
Operating Expenses
-1.2B CNY
Operating Income
-730.9m CNY
Other Expenses
-155.7m CNY
Net Income
-886.6m CNY

Free Cash Flow Analysis
InnoCare Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative ROE
28/100
Profitability
Score

InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

InnoCare Pharma Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
73/100
Solvency
Score

InnoCare Pharma Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
InnoCare Pharma Ltd

Wall Street analysts forecast InnoCare Pharma Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 16.22 CNY with a low forecast of 16.06 CNY and a high forecast of 16.7 CNY.

Lowest
Price Target
16.06 CNY
21% Upside
Average
Price Target
16.22 CNY
22% Upside
Highest
Price Target
16.7 CNY
26% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for InnoCare Pharma Ltd?

Click here to dive deeper.

Dividends

InnoCare Pharma Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for InnoCare Pharma Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd

Country

China

Industry

Biotechnology

Market Cap

11.2B CNY

Dividend Yield

0%

Description

InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-03-23. The firm discovers, develops and commercializes potentially best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The firm builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Contact

BEIJING
Beijing
Building 8, No. 8 Shengmingyuan Road, Zhongguancun Science Park, Changping District
www.innocarepharma.com

IPO

2020-03-23

Employees

531

Officers

Co-Founder, Chairwoman & CEO
Dr. Jisong Cui Ph.D.
VP of Clinical Development & Medical Research and Executive Director
Dr. Renbin Zhao Ph.D.
Chief Financial Officer
Mr. Xin Fu
Chief Operating Officer
Mr. Nan Gao
Accounting Supervisor
Yue Tan
Chief Technology Officer
Dr. Xiangyang Chen Ph.D.
Show More
General Counsel
Ms. Junsu Wang
VP & Head of Biology
Mr. Davy Ouyang Ph.D.
Chief Commercial Officer
Mr. Jeff Chen
Secretary of the Board
Bei Yuan
Show Less

See Also

Discover More